A patient with debrided MRSA calcaneal osteomyelitis has completed 14 days of IV vancomycin. The isolate is susceptible to clindamycin,

Question

A patient with debrided MRSA calcaneal osteomyelitis has completed 14 days of IV vancomycin. The isolate is susceptible to clindamycin, co-trimoxazole, doxycycline and linezolid; there is no retained metalwork. Which oral-completion principle best follows the UK MRSA guideline?

Accepted Answer

Complete at least six weeks, using an active oral agent after vancomycin

Answer

Complete eight weeks total treatment, switching routinely to linezolid after two weeks

Answer

Complete four weeks total treatment, switching to susceptible clindamycin after two weeks

Answer

Complete six weeks total treatment, switching to rifampicin monotherapy after two weeks

Answer

Complete twelve weeks total treatment, continuing intravenous vancomycin throughout

MRSA Osteomyelitis Oral Step-Down — SCE Infectious Diseases MCQ

A patient with debrided MRSA calcaneal osteomyelitis has completed 14 days of IV vancomycin. The isolate is susceptible to clindamycin, co-trimoxazole, doxycycline and linezolid; there is no retained metalwork. Which oral-completion principle best follows the UK MRSA guideline?